TW201513882A - 抗－催乳激素受體抗體調配物 - Google Patents

抗－催乳激素受體抗體調配物 Download PDF

Info

Publication number
TW201513882A
TW201513882A TW103109457A TW103109457A TW201513882A TW 201513882 A TW201513882 A TW 201513882A TW 103109457 A TW103109457 A TW 103109457A TW 103109457 A TW103109457 A TW 103109457A TW 201513882 A TW201513882 A TW 201513882A
Authority
TW
Taiwan
Prior art keywords
prlr antibody
prlr
antibody formulation
antibody
formulation
Prior art date
Application number
TW103109457A
Other languages
English (en)
Chinese (zh)
Inventor
Xing-Hang Ma
Jian-Jie Niu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TW201513882A publication Critical patent/TW201513882A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW103109457A 2013-03-15 2014-03-14 抗－催乳激素受體抗體調配物 TW201513882A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
TW201513882A true TW201513882A (zh) 2015-04-16

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103109457A TW201513882A (zh) 2013-03-15 2014-03-14 抗－催乳激素受體抗體調配物

Country Status (10)

Country Link
US (2) US9023357B2 (enExample)
EP (1) EP2968538A1 (enExample)
JP (1) JP2016515515A (enExample)
CN (1) CN105025925A (enExample)
AR (1) AR095496A1 (enExample)
CA (1) CA2906101A1 (enExample)
HK (1) HK1215175A1 (enExample)
TW (1) TW201513882A (enExample)
UY (1) UY35460A (enExample)
WO (1) WO2014143909A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631565A (en) 2012-03-14 2016-07-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017104778A1 (ja) 2015-12-18 2017-06-22 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
MA46988A1 (fr) * 2017-03-16 2020-06-30 Lg Chemical Ltd Formulation liquide d'anticorps anti-tnf alpha
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
LT3743088T (lt) * 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR20250120995A (ko) 2022-11-07 2025-08-11 업스트림 바이오, 인크. 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3018144A1 (en) * 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
JP5401314B2 (ja) * 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
BRPI0918419A2 (pt) * 2008-09-19 2015-11-24 Hoffmann La Roche nova formulação anticorpo
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
CN102686241A (zh) 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤

Also Published As

Publication number Publication date
US9023357B2 (en) 2015-05-05
JP2016515515A (ja) 2016-05-30
CN105025925A (zh) 2015-11-04
US20160002342A1 (en) 2016-01-07
CA2906101A1 (en) 2014-09-18
HK1215175A1 (zh) 2016-08-19
US20140271659A1 (en) 2014-09-18
AR095496A1 (es) 2015-10-21
UY35460A (es) 2014-10-31
WO2014143909A1 (en) 2014-09-18
EP2968538A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2890397B1 (en) Anti-prolactin receptor antibody formulations
US9023357B2 (en) Anti-prolactin receptor antibody formulations
TW201414496A (zh) 抗體及蛋白質配方
US20150044206A1 (en) Immunoglobulin formulation and method of preparation thereof
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
HK40020980A (en) Anti-prolactin receptor antibody formulations
HK40020981A (en) Anti-prolactin receptor antibody formulations
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
TW202237185A (zh) Ｈｅｒ２／ｎｅｕ抗體的藥物組合物及其用途
HK1207316B (zh) 抗催乳素受体抗体制剂